In-vitro activity of the new ketolide antibiotic HMR 3647 against gram-positive bacteria. 1998

T Schülin, and C B Wennersten, and R C Moellering, and G M Eliopoulos
Department of Medicine, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA 02115, USA.

The comparative in-vitro activity of HMR 3647, a new ketolide antibiotic, was investigated against 492 clinical isolates of gram-positive bacteria, including multiply resistant strains, by an agar-dilution technique. All streptococci tested were inhibited by the new ketolide at concentrations < or = 0.5 mg/L. HMR 3647 was more potent than erythromycin against staphylococci. For enterococci the new compound yielded an MIC90 of 8 mg/L. Erysipelothrix spp., Pediococcus spp., Leuconostoc spp., Lactobacillus spp., JK diphtheroids and Listeria monocytogenes were also susceptible to the new ketolide.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D006094 Gram-Positive Bacteria Bacteria which retain the crystal violet stain when treated by Gram's method. Gram Positive Bacteria
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D048628 Ketolides Compounds based on ERYTHROMYCIN with the 3-cladinose replaced by a ketone. They bind the 23S part of 70S bacterial RIBOSOMES. 3-Keto-Erythromycins,Erythromycins, 3-Keto,3 Keto Erythromycins,3-Keto Erythromycins,Erythromycins, 3 Keto
D018432 Drug Resistance, Multiple Simultaneous resistance to several structurally and functionally distinct drugs. Drug Resistance, Extensively,Extensively Drug Resistance,Extensively-Drug Resistance,Multidrug Resistance,Multi-Drug Resistance,Extensively Drug Resistances,Extensively-Drug Resistances,Multiple Drug Resistance,Resistance, Extensively Drug,Resistance, Extensively-Drug,Resistance, Multiple Drug
D018942 Macrolides A group of often glycosylated macrocyclic compounds formed by chain extension of multiple PROPIONATES cyclized into a large (typically 12, 14, or 16)-membered lactone. Macrolides belong to the POLYKETIDES class of natural products, and many members exhibit ANTIBIOTIC properties. Macrolide

Related Publications

T Schülin, and C B Wennersten, and R C Moellering, and G M Eliopoulos
June 1998, Antimicrobial agents and chemotherapy,
T Schülin, and C B Wennersten, and R C Moellering, and G M Eliopoulos
April 1999, Antimicrobial agents and chemotherapy,
T Schülin, and C B Wennersten, and R C Moellering, and G M Eliopoulos
August 1998, Antimicrobial agents and chemotherapy,
T Schülin, and C B Wennersten, and R C Moellering, and G M Eliopoulos
September 2001, Drugs of today (Barcelona, Spain : 1998),
T Schülin, and C B Wennersten, and R C Moellering, and G M Eliopoulos
December 1998, Antimicrobial agents and chemotherapy,
T Schülin, and C B Wennersten, and R C Moellering, and G M Eliopoulos
December 1998, The Journal of antimicrobial chemotherapy,
T Schülin, and C B Wennersten, and R C Moellering, and G M Eliopoulos
June 1998, The Journal of antimicrobial chemotherapy,
T Schülin, and C B Wennersten, and R C Moellering, and G M Eliopoulos
August 1998, Journal of chemotherapy (Florence, Italy),
T Schülin, and C B Wennersten, and R C Moellering, and G M Eliopoulos
June 1998, Antimicrobial agents and chemotherapy,
T Schülin, and C B Wennersten, and R C Moellering, and G M Eliopoulos
March 2001, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!